TriSalus Life Sciences Inc. (TLSI) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

TriSalus Life Sciences In... (TLSI)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

4.69

-0.37 (-7.31%)

At close: Jan 14, 2025, 2:53 PM

4.69

0.00%

After-hours Jan 14, 2025, 02:54 PM EST

undefined% (undefined)

Bid	4.14
Market Cap	143.01M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.92
PE Ratio (ttm)	-2.44
Forward PE	n/a
Analyst	Buy

Ask	5.98
Volume	10,435
Avg. Volume (20D)	37,708
Open	4.83
Previous Close	5.06
Day's Range	4.62 - 4.91
52-Week Range	3.50 - 10.42
Beta	undefined

About TLSI

TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular...

[Show more]

Industry Medical - Devices

Sector Healthcare

IPO Date Feb 8, 2021

Employees 107

Stock Exchange NASDAQ

Ticker Symbol TLSI

Website https://trisaluslifesci.com

Analyst Forecast

According to 6 analyst ratings, the average rating for TLSI stock is "Buy." The 12-month stock price forecast is $11, which is an increase of 134.54% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

TriSalus Life Sciences Inc. is scheduled to release its earnings on Mar 31, 2025, before market opens.
Analysts project revenue of $8.22M, reflecting a 43.68% YoY growth and earnings per share of -0.31, making a -80.13% decrease YoY.

Why Price Moved

2 months ago · Source

-10.89%

TriSalus Life Sciences shares are trading lower af... Unlock content with Pro Subscription

News

3 weeks ago · seekingalpha.com

TriSalus Life Sciences: Continuing To Maintain Optimism As Costs Are Cut

TriSalus Life Sciences continues to develop its TriNav infusion system, expanding its reach in liver and pancreatic cancer treatment, despite shifting focus from drug development. TLSI's financials sh...

2 months ago · seekingalpha.com

TriSalus Life Sciences, Inc. (TLSI) Q3 2024 Earnings Call Transcript

TriSalus Life Sciences, Inc. (NASDAQ:TLSI ) Q3 2024 Earnings Conference Call November 14, 2024 9:00 AM ET Company Participants Jim Young - Senior Vice President, Investor Relations & Treasurer Mary Sz...

2 months ago · businesswire.com

TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients suffering from liver cancer through...

2 months ago · https://thefly.com

TriSalus Life Sciences initiated with a Buy at Roth MKM

Roth MKM analyst Jason Wittes initiated coverage of TriSalus Life Sciences with a Buy rating and $11 price target. The company's TriNav catheter significantly improves drug delivery with pressure enab...

2 months ago · businesswire.com

TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery t...